Melio
Developer of a culture-free bloodborne pathogen testing platform (in development) that integrates proprietary molecular assays, microfluidics, and machine-learning analytics to identify pathogens from blood samples within hours. The system is described as not yet commercialized.
Industries
biotechnology
health-care
health-diagnostics
Nr. of Employees
small (1-50)
Melio
Santa Clara, California, United States, North America
Patents
Products
Bloodborne pathogen testing platform (in development)
A culture-free diagnostic platform integrating molecular assays, microfluidics, and machine-learning analytics to identify bloodborne pathogens within hours; currently described as under development and not commercialized.
Bloodborne pathogen testing platform (in development)
A culture-free diagnostic platform integrating molecular assays, microfluidics, and machine-learning analytics to identify bloodborne pathogens within hours; currently described as under development and not commercialized.
Expertise Areas
- Infectious disease diagnostics
- Molecular assay development
- Microfluidics engineering
- Machine learning for diagnostics
Key Technologies
- DNA melt-curve analysis
- Microfluidics
- Machine learning / AI-driven analytics
- Cloud/over-the-air software updates